Table 6 Feasibility of MRDT proposals to promote R&D for neglected diseases
From: Expert Delphi survey on research and development into drugs for neglected diseases
| Â | Â | % (n) | % (n) | % (n) | % (n) | % (n) | Â | Â |
|---|---|---|---|---|---|---|---|---|
| Â | Â | definitely feasible | feasible | unfeasible | definitely unfeasible | no judgment | Total valid % (n) | Total N |
Prize funds with prizes awarded based on degree of innovation | Round I | 20.9% (23) | 60.0% (23) | 4.5% (5) | 0.9% (1) | 13.6% (15) | 110 | 159 |
| Â | Round II | 30.8% (16) | 48.1% (25) | 11.5% (6) | 1.9% (1) | 7.7% (4) | 52 | 77 (25) |
Obligation for national governments to invest into neglected disease R&D | Round I | 28.2% (31) | 41.8% (46) | 20.0% (22) | 5.5% (6) | 4.5% (5) | 110 | 159 (49) |
| Â | Round II | 11.3% (6) | 43.4% (23) | 35.8% (19) | 3.8% (2) | 5.7% (3) | 53 | 77 (24) |
Separation of innovation incentives from drug prices | Round I | 12.6% (14) | 39.6% (44) | 11.7% (13) | 6.3% (7) | 29.7% (33) | 111 | 159 (48) |
| Â | Round II | 15.1% (8) | 41.5% (22) | 11.3% (6) | 9.4% (5) | 22.6% (12) | 53 | 77 (24) |